Chronic Myeloid Leukemia Current Events | Chronic Myeloid Leukemia News | 2
|
| Page
2 of
36 |
709 Results |
|
|
|
Sort By:
Page Views | Date |
Data presented demonstrate prolonged overall survival for patients with acute myeloid leukemia
The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with... view more... (2008-12-11)
New hope for patients with chronic lymphocytic leukemia
Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI). The results are published in the December... view more... (2006-12-05)
The genetics of MLL leukemogenesis
In the November 1st issue of G&D, Dr. Michael Cleary (Stanford University School of Medicine) and colleagues identify the gene Meis1 as a critical player in the establishment of leukemia stem cells, and the development of MLL leukemia. view more (2007-10-17)
Therapeutic effect of imatinib improved with addition of chloroquine
The therapeutic effects of the blockbuster leukemia drug imatinib may be enhanced when given along with a drug that inhibits a cell process called autophagy, researchers from the Kimmel Cancer Center at Jefferson reported in the Journal of Clinical Investigation. view more (2009-04-14)
Lenalidomide safe as single therapy for elderly CLL patients
The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology. view more (2008-12-08)
Leukemia drug proves safe and effective over the long term
The drug imatinib mesylate, more commonly known as Gleevec, proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML), according to a study prepublished online in Blood, the official journal of the American Society of Hematology. view more (2007-11-08)
Rate of secondary cancers increases over years after treatment for childhood leukemia
Survivors of acute lymphoblastic leukemia have a significantly increased risk of secondary cancers developing over 30 years after leukemia treatment when compared to the general population. view more (2007-03-21)
Combining math and medicine to treat leukemia
Researchers have produced a mathematical model that may lead to the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML). view more (2008-06-20)
Researchers find drug that inhibits acute leukemia cell growth
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells. view more (2009-04-27)
Experimental agents may prevent radiation-induced leukemia
Treatment with biphosphonates could prevent radiation-induced leukemia, according to data presented at the American Association for Cancer Research 100th Annual Meeting 2009. view more (2009-04-20)
Molecules might identify high-risk acute-leukemia patients
New research suggests that certain small molecules used by cells to control the proteins they make might also help doctors identify adult acute-leukemia patients who are likely to respond poorly to therapy. view more (2008-01-16)
Toronto researcher's discovery points to a new treatment avenue for acute myeloid leukemia
Dr. John Dick, Senior Scientist at the Ontario Cancer Institute, the research arm of Princess Margaret Hospital, co-led a multinational team that has developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome. view more (2009-07-07)
Cells on path to becoming mature T-cells more flexible than commonly thought
Contrary to the currently accepted model of T-cell development, researchers at the University of Pennsylvania School of Medicine have found that juvenile cells on their way to becoming mature immune cells can develop into either T cells or other blood-cell types versus only being committed to the T-cell path. view more (2008-04-10)
U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence
A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. view more (2009-11-16)
New strategy rapidly identifies cancer targets
In a step toward personalized medicine, Howard Hughes Medical Institute investigator Brian J. Druker and colleagues have developed a new technique to identify previously unknown genetic mutations that can trigger cancerous growth. view more (2006-07-17)
CDX2 — A protein that promotes leukemia
Researchers from Harvard Medical School, Boston, have found that most individuals with acute myeloid leukemia (AML) inappropriately express a protein known as CDX2 in their leukemic cells. view more (2007-03-08)
How cells change gears: New insights published in Nature Genetics
Bioinformatics researchers from UC San Diego just moved closer to unlocking the mystery of how human cells switch from "proliferation mode" to "specialization mode." This computational biology work from the Jacobs School of Engineering's bioengineering department could lead to new ideas for curbing unwanted cell... view more... (2009-04-21)
Arsenic-based therapy shown to help eradicate leukemia-initiating cells
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. view more (2008-05-13)
Pair of microRNA molecules controls major oncogene in most common leukemia
Researchers at Ohio State University have discovered that two microRNA (miRNA) molecules help control the oncogene responsible for a dangerous form of B-cell chronic lymphocytic leukemia (B-CLL), the most common human leukemia in the world. view more (2006-12-18)
Daisies lead scientists down path to new leukemia drug
A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood. view more (2007-10-03)
|
|
| Page
2 of
36 |
709 Results |
|
|
|
Sort By:
Page Views | Date |
|
